Anticoagulant

Phase 3Small molecule

Bayer

Anticoagulant is one of 139 small molecule programs targeting Venous Thromboembolism. It is currently in Phase 3.

Indications

Total Trials

Active Trials

138

Competitors

Pipeline

Status by Indication[3][1]

Indication

Venous ThromboembolismActive, not recruiting

StrokeActive, not recruiting

Venous ThrombosisActive, not recruiting

Intracranial HemorrhageActive, not recruiting

AtherosclerosisActive, not recruiting

Atrial FibrillationRecruiting

Venous ThromboembolismPreclinical

Active, not recruiting

StrokePreclinical

Active, not recruiting

Venous ThrombosisPreclinical

Active, not recruiting

Intracranial HemorrhagePreclinical

Active, not recruiting

AtherosclerosisPreclinical

Active, not recruiting

Atrial FibrillationPhase 3

Recruiting

Competition

Competitive Landscape

150 competitors in Stroke

#DrugCompanyPhaseTrials

Anticoagulant

Bayer

Phase 3

1 2

Zometa

Pfizer

Preclinical

1 3

Savella

AbbVie

Preclinical

1 4

Proamatine

Repatha

Periactin

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 7

Zantac 150

CChattem

Preclinical

1 8

Alka-Seltzer

AAbbott

Preclinical

1 9

Haldol

DDePuy Orthopaedics

Preclinical

1 10

Inderal

Mylan Pharmaceuticals Inc

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Recruiting

Thrombosis

NCT06284343

Q4 2026

Post-ApprovalRecruiting

Atrial Fibrillation

NCT06402851

Q1 2028

Recruiting

Venous Thrombosis

NCT04660747

Q4 2028

Recruiting

Atherosclerosis

NCT04847752

Clinical

Trials by Indication[1]

Atrial Fibrillation9 trials

Subclinical AtrIal FibrilLation and StrokE PreveNtion Trial

Unknown status·IInCor Heart Institute·Phase 4·NCT02004509·2,054 enrolled

Association of Obesity and Cardiovascular Outcomes in Atrial Fibrillation

Unknown status·—··NCT05645913·56,272 enrolled

Vitamin K AntagonISt, Factor Xa Inhibitor or No Anticoagulation in Atrial Fibrillation and DIalytic End-stage Renal DiseasE (VISIONAIRE)

Recruiting·HHospital Sirio-Libanes·Phase 4·NCT06402851·1,500 enrolled

Show 6 more trials

Use of Oral Anticoagulants and Symptoms in Patients With Atrial Fibrillation in Örebro County

Completed·RRegion Örebro County··NCT04233515·11,964 enrolled

Optimal Antithrombotic Therapy in Ischemic Stroke Patients with Non-Valvular Atrial Fibrillation and Atherothrombosis

Terminated·NNational Hospital Organization Osaka National Hospital·Phase 4·NCT03062319·321 enrolled

Risk of Stroke and Silent Cerebrovascular Thromboembolism After Cardioversion of Atrial Fibrillation

Completed·SSuleyman Demirel University·Phase 3·NCT01924065·112 enrolled

Burden of Ischemic Stroke and Intake of Oral Anticoagulants in Patients With Atrial Fibrillation in the UK Primary Care

Completed· Bayer logo

Bayer··NCT04099238·3,739 enrolled

Obesity Paradox in Non Valvular Atrial Fibrillation Regarding Outcomes: Fact or Fiction

Unknown status·—··NCT03904329·1 enrolled

A Trial of Pharmacist Management of Oral Anticoagulation THerapy Versus Enhanced Usual CARe in the communitY for AF (APOTHECARY AF Study)

Completed·CCedars-Sinai Medical Center·Approved·NCT04907825·14 enrolled

Anticoagulant2 trials

Anticoagulants for PFO Patients

Completed·XXuanwu Hospital, Beijing··NCT06375070·277 enrolled

Anticoagulant Clinics and Vitamin K Antagonists

Completed·UUniversity Hospital, Toulouse·Phase 4·NCT00966290·1,006 enrolled

Anticoagulation2 trials

Anticoagulation After RFCA

Unknown status·YYong Seog Oh·N/A·NCT03573037·246 enrolled

Combination of Antiplatelet and Anticoagulation for AIS Patients Witn Concomitant NVAF and Extracranial/Intracranial Artery Stenosis

Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·N/A·NCT06058130·2,171 enrolled

Anticoagulant Therapy1 trial

Efficacy and Safety of Extended Anticoagulant Therapy in Cancer Associated Thrombosis in Thai Population

Completed·TThammasat University··NCT07388056·169 enrolled

Intracranial Hemorrhage1 trial

Anticoagulant-associated Intracranial Hemorrhage

Unknown status·EEl Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez··NCT06168838·1,200 enrolled

8 more indications

Thrombosis1 trial

The Gynecological Cancer Associated Thrombosis (GynCAT) Study

Recruiting·FFondazione Policlinico Universitario Agostino Gemelli IRCCS··NCT06284343·1,800 enrolled

Trial1 trial

Prognostic Value of Precision Medicine in Patients With MINOCA (PROMISE Trial).

Active, not recruiting·FFondazione Policlinico Universitario Agostino Gemelli IRCCS·Phase 4·NCT05122780·120 enrolled

Stroke1 trial

Carotid Web and Stroke Registry.

Unknown status·FFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau··NCT05475080·100 enrolled

Atherosclerosis1 trial

Study of Predictive Factors Related to Prognosis of Patients With Ischemic Stroke Due to Large-artery Atherosclerosis

Recruiting·TTongji Hospital··NCT04847752·1,000 enrolled

Venous Thromboembolism1 trial

Anticoagulation Length of ThErapy and Risk of New Adverse evenTs In Venous thromboEmbolism Study

Completed·UUniversity of California, San Francisco··NCT03292666·39,603 enrolled

Venous thrombosis1 trial

Direct Oral Anticoagulants for the Treatment of Cerebral Venous Thrombosis

Recruiting·—··NCT04660747·1,300 enrolled

GIST1 trial

CHAOS Registry Study

Unknown status·AA.O.U. Città della Salute e della Scienza··NCT03558295·1,000 enrolled

Clinical Trial1 trial

To Determine the Feasibility of a Clinical Trial Comparing Anticoagulants Versus Antiplatelets in the Acute Treatment of Patients With Cervical Artery Dissection

Completed·SSt George's, University of London·Phase 3·NCT00238667·250 enrolled

Sources

References

[1]
ClinicalTrials.gov — 23 trial records for Anticoagulant. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Anticoagulant compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Anticoagulant. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bayer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Bayer

Anticoagulant

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Q1 2028

Q4 2028

Trials by Indication[1]

Atrial Fibrillation9 trials

Anticoagulant2 trials

Anticoagulation2 trials

Anticoagulant Therapy1 trial

Intracranial Hemorrhage1 trial

Thrombosis1 trial

Trial1 trial

Stroke1 trial

Atherosclerosis1 trial

Venous Thromboembolism1 trial

Venous thrombosis1 trial

GIST1 trial

Clinical Trial1 trial

References

Drug Info

Quick Facts

Related News